Pharma Mar (XMAD:PHM) Short Percentage of Float

View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Pharma Mar's Short Percentage of Float

For the Biotechnology subindustry, Pharma Mar's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Mar's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Short Percentage of Float falls into.

Pharma Mar (XMAD:PHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

PHMMF:USA PHMe:UK 0RC6:UK

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.